 |
 |
OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer
EDMONTON, November 2, 2016 - OncoQuest Inc., a private, Canadian biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, announced that its Joint Venture Partner in China-based, OncoVent Co., Ltd. has launched its clinical development program for Anti-MUC1 MAb AR20.5 for the treatment of pancreatic cancer.
Based on previous clinical experience and recently announced positive pre-clinical data on combinatory immunotherapy in the pancreatic cancer model, OncoVent has started implementing its clinical development plan, and has signed an agreement with a U.S. based cGMP cell culture bioproduction facility, Cell Culture Company (C3), located in Minneapolis US, to manufacture clinical grade MAb AR20.5. The manufactured antibody is intended to be used to support a planned U.S. clinical trial for the treatment of pancreatic cancer, followed by additional studies worldwide, including China.